Mar 26, 2026Nirsevimab for Infant RSV: What Real-World Data ShowNirsevimab cuts infant RSV hospitalizations in real-world studies, but does it outperform trials? Evidence, bias, costs, and coverage shape the answer.nirsevimabrsv preventionmonoclonal antibodyRead article →